Literature DB >> 26635131

Lymph node status of lateral neck compartment in patients with N1b papillary thyroid carcinoma.

Young Min Park1, Soo-Geun Wang2, Dong Hoon Shin3, In-Ju Kim4, Seok-Man Son5, Byung-Joo Lee2.   

Abstract

Conclusion Loco-regional recurrence-free survival was significantly decreased in the papillary thyroid cancer patients with > 6 metastatic lymph nodes and a lymph node ratio > 0.22. Also, the risk of lung metastasis was significantly increased in cases with bilateral neck node metastases. Objective This study focused on the metastatic lymph node status of the lateral neck compartment to understand its prognostic significance for loco-regional recurrence and distant metastasis. Methods Between January 2004 and December 2009, 1040 patients were diagnosed with papillary thyroid cancer and underwent treatment. Results In a multivariate analysis, sex, the number of metastatic lymph nodes, and the lymph node ratio was significantly associated with loco-regional recurrence. The sensitivity/specificity of > 6 metastatic lymph nodes for predicting recurrence was 64.0%/69.7%. The 5-year loco-regional recurrence-free survival of patients with 0-6 metastatic lymph nodes and > 6 metastatic lymph nodes were 93.4% and 79.2%, respectively. The 5-year loco-regional recurrence-free survival of patients with a lymph node ratio ≤ 0.22 and a lymph node ratio > 0.22 were 97.1% and 78.8%, respectively. In the multivariate analysis, only bilateral neck node metastases were significantly associated with lung metastasis.

Entities:  

Keywords:  Recurrence; lymph node status; papillary thyroid cancer

Mesh:

Year:  2015        PMID: 26635131     DOI: 10.3109/00016489.2015.1116045

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  8 in total

1.  Macroscopic extranodal extension is an independent predictor of lung metastasis in papillary thyroid cancer.

Authors:  Hu Hei; Wenbo Gong; Chen Zheng; Bin Zhou; Jianwu Qin
Journal:  Endocrine       Date:  2022-04-07       Impact factor: 3.925

2.  Risk factors of suprasternal lymph node metastasis in papillary thyroid carcinoma with clinical lateral cervical lymph node metastasis.

Authors:  Hyun-Keun Kwon; Yong-Il Cheon; Sung-Chan Shin; Eui-Suk Sung; Jin-Choon Lee; In Ju Kim; Byung-Joo Lee
Journal:  Gland Surg       Date:  2021-02

3.  Predictive factors of right paraesophageal lymph node metastasis in papillary thyroid carcinoma: Single center experience and meta-analysis.

Authors:  Young Min Park; Sang Min Lee; Dong Won Kim; Sung-Chan Shin; Byung-Joo Lee
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

4.  Prognostic Role of Metastatic Lymph Node Ratio in Papillary Thyroid Carcinoma.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Kyungseek Chang
Journal:  J Pathol Transl Med       Date:  2018-08-30

5.  Using Diffusion-Weighted MRI to Predict Central Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Feasibility Study.

Authors:  Heng Zhang; Shudong Hu; Xian Wang; Wenhua Liu; Junlin He; Zongqiong Sun; Yuxi Ge; Weiqiang Dou
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-12       Impact factor: 5.555

6.  Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine.

Authors:  Canhua Yun; Juan Xiao; Jingjia Cao; Chunchun Shao; Lihua Wang; Wei Zhang; Hongying Jia
Journal:  Cancer Med       Date:  2021-10-08       Impact factor: 4.452

7.  Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma.

Authors:  Il Ku Kang; Kwangsoon Kim; Joonseon Park; Ja Seong Bae; Jeong Soo Kim
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

8.  Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size.

Authors:  Hye In Kim; Tae Hyuk Kim; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Young Lyun Oh; Soo Yeon Hahn; Jung Hee Shin; Hye Won Jang; Young Nam Kim; Hosu Kim; Hyeon Seon Ahn; Kyunga Kim; Sun Wook Kim; Jae Hoon Chung
Journal:  Cancer Med       Date:  2017-08-31       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.